Asthma, COPD, and asthma–COPD overlap: A comparative study of inflammatory biomarkers and quality of life Authors: M Ahmed Safwan, Nitin Goel, Raj Kumar Published: 2026 ABSTRACT ABSTRACTBackground:Asthma, COPD, and ACO are chronic airway disorders with distinct and overlapping features. This study aimed to compare clinical profiles, inflammatory biomarkers, and quality of life among these groups.Methods:A cross-sectional study was conducted on 168 patients (56 each with asthma, COPD, and ACO). All participants underwent clinical assessment, spirometry, St George’s Respiratory Questionnaire (SGRQ), skin prick testing, and measurement of inflammatory markers, including FeNO, eosinophil count, total IgE, vitamin D, hs-CRP, and interleukins (IL-4, 5, 6, 8, 13, 17, 33).Results:ACO patients were younger than COPD patients but older than asthma patients. Asthma patients had the highest prevalence of allergic rhinitis and skin prick positivity. FEV1 and FEV1/FVC were significantly lower in COPD and ACO compared to asthma, but not different between COPD and ACO. Bronchodilator response was higher in asthma and ACO than in COPD. Asthma patients had significantly higher FeNO, eosinophil counts, and IgE levels compared to COPD, with ACO showing intermediate values. IL-4 and IL-5 were highest in asthma, IL-6 and IL-8 in COPD, with ACO again showing intermediate levels. ACO patients had the highest SGRQ scores, indicating the worst quality of life. Correlation analysis showed group-specific associations between interleukins and clinical parameters.Conclusion:ACO exhibits intermediate clinical and inflammatory profiles between asthma and COPD. While individual biomarkers assist in characterizing these diseases, a combination of clinical, functional, and inflammatory parameters offers better differentiation. ACO patients experience a significant symptom burden, necessitating tailored diagnostic and therapeutic approaches. INTRODUCTION COPD and asthma are the two major chronic airway inflammatory diseases, and both are characterized by airflow limitation. COPD is currently the fourth leading cause of mortality in the world.[1] Asthma is one of the most common chronic diseases globally and currently affects ~300 million people.[2] In some patients, features of both diseases may coexist. They are commonly known as asthma–COPD overlap (ACO), as proposed by Global Initiative for Asthma/Global Initiative for Chronic Obstructive Lung Disease (GINA/GOLD) statement and other working groups.[234] However, its exact definition has not been established till now.[56] More rapid disease progression, frequent exacerbation, and worse disease-related quality of life are reported to be associated with ACO compared with COPD or asthma alone.[78] Airway inflammation is a central process in the pathogenesis of such chronic lung diseases. Typically, asthma is characterized by inflammation predominantly involving eosinophils, whereas COPD is characterized by inflammation by neutrophils.[9] Th2 cells orchestrate the inflammatory response in asthma through the release involving cytokines such as IL-4, 5, 9, and 13, whereas in COPD, the neutrophil chemokine IL-8 and proinflammatory cytokines IL-1 and TNF−α play a major role.[9] Also, the eosinophilic inflammation in some COPD patients and the increased neutrophilic expression occurring in patients with severe uncontrolled asthma have been reported.[10] However, the importance of these inflammatory biomarkers in the diagnosis of ACO remains unclear. Hence, in the present study we tried to identify the inflammatory biomarkers relevant for airway inflammation in asthma, COPD, and ACO. We also compared the quality of life in the above groups. MATERIAL AND METHODS This observational cross-sectional study was conducted in the Department of Pulmonary Medicine at a tertiary care teaching institute from April 2019 to March 2020. The study protocol was approved by the Institutional Ethics Committee, and informed written consent was obtained from all participants before enrolment. Study population Patients diagnosed with Asthma (according to GINA 2018 guidelines), COPD (according to GOLD 2018 guidelines), and asthma–COPD overlap (ACO) (according to GINA 2018 guidelines) were included in the study.[12] Patients younger than 18 years, pregnant or lactating women, and patients with a history of systemic steroid use or hospital admission within the past four weeks were excluded. Sample size calculation The sample size for this study was calculated assuming an effect size of 0.5,[11] with a power of 80% and a significance level of 5%. The sample size for each group was 56, accounting for potential dropouts. Hence, a total number of 168 patients were enrolled in this study with 56 patients in each of the three groups (asthma group, COPD group, and ACO group). Data collection and assessments Clinical History: Detailed clinical history, including sociodemographic characteristics, respiratory symptoms, smoking status, presence of rhinitis, and history of exacerbations, was collected for each patient.Dyspnoea Assessment: Dyspnoea was evaluated using the modified Medical Research Council (mMRC) dyspnoea scale.[12]Health-Related Quality of Life: It was assessed using the St George’s Respiratory Questionnaire (SGRQ), with scoring performed according to standard guidelines.[13]SpirometrySpirometry was conducted using a dry, rolling-seal spirometer (Benchmark model, P.K. Morgan, Kent, UK). Maximal expiratory flow volume curves were obtained as per the ATS recommendations. Dynamic lung volumes, including forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), were measured according to the guidelines.[14] Prediction equations for North Indian adults were used to calculate percent predicted values.[15]Skin Prick Tests (SPT)SPT was performed using a battery of 58 common aeroallergens, following Indian guidelines.[16] Allergen extracts (1:10 w/v, 50% glycerinated) were procured from All Cure Pharma Pvt. Ltd., New Delhi. Skin test reactions were graded according to the Indian standard protocol.[16]Measurement of Inflammatory BiomarkersFractional Exhaled Nitric Oxide (FENO): FENO was measured using a NIOX chemiluminescence analyser (Aerocrine AB, Solna, Sweden) in accordance with the 2005 American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations.[17] The flow rate of 50 mL/s was used for standardizationBlood Samples: Blood samples were collected to measure absolute eosinophil count, serum total IgE, vitamin D, high sensitivity C-reactive protein (Hs-CRP), and interleukins 4, 5, 6, 8, 13, 17, and 33. These biomarkers were quantified using enzyme-linked immunosorbent assay (ELISA) with standardized kits according to the manufacturer’s protocol (Diaclone, Calbiotech).® Clinical History: Detailed clinical history, including sociodemographic characteristics, respiratory symptoms, smoking status, presence of rhinitis, and history of exacerbations, was collected for each patient. Clinical History: Detailed clinical history, including sociodemographic characteristics, respiratory symptoms, smoking status, presence of rhinitis, and history of exacerbations, was collected for each patient. Dyspnoea Assessment: Dyspnoea was evaluated using the modified Medical Research Council (mMRC) dyspnoea scale.[12] Dyspnoea Assessment: Dyspnoea was evaluated using the modified Medical Research Council (mMRC) dyspnoea scale.[12] Health-Related Quality of Life: It was assessed using the St George’s Respiratory Questionnaire (SGRQ), with scoring performed according to standard guidelines.[13] Health-Related Quality of Life: It was assessed using the St George’s Respiratory Questionnaire (SGRQ), with scoring performed according to standard guidelines.[13] SpirometrySpirometry was conducted using a dry, rolling-seal spirometer (Benchmark model, P.K. Morgan, Kent, UK). Maximal expiratory flow volume curves were obtained as per the ATS recommendations. Dynamic lung volumes, including forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), were measured according to the guidelines.[14] Prediction equations for North Indian adults were used to calculate percent predicted values.[15] Spirometry Spirometry was conducted using a dry, rolling-seal spirometer (Benchmark model, P.K. Morgan, Kent, UK). Maximal expiratory flow volume curves were obtained as per the ATS recommendations. Dynamic lung volumes, including forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), were measured according to the guidelines.[14] Prediction equations for North Indian adults were used to calculate percent predicted values.[15] Skin Prick Tests (SPT)SPT was performed using a battery of 58 common aeroallergens, following Indian guidelines.[16] Allergen extracts (1:10 w/v, 50% glycerinated) were procured from All Cure Pharma Pvt. Ltd., New Delhi. Skin test reactions were graded according to the Indian standard protocol.[16] Skin Prick Tests (SPT) SPT was performed using a battery of 58 common aeroallergens, following Indian guidelines.[16] Allergen extracts (1:10 w/v, 50% glycerinated) were procured from All Cure Pharma Pvt. Ltd., New Delhi. Skin test reactions were graded according to the Indian standard protocol.[16] Measurement of Inflammatory BiomarkersFractional Exhaled Nitric Oxide (FENO): FENO was measured using a NIOX chemiluminescence analyser (Aerocrine AB, Solna, Sweden) in accordance with the 2005 American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations.[17] The flow rate of 50 mL/s was used for standardizationBlood Samples: Blood samples were collected to measure absolute eosinophil count, serum total IgE, vitamin D, high sensitivity C-reactive protein (Hs-CRP), and interleukins 4, 5, 6, 8, 13, 17, and 33. These biomarkers were quantified using enzyme-linked immunosorbent assay (ELISA) with standardized kits according to the manufacturer’s protocol (Diaclone, Calbiotech).® Measurement of Inflammatory Biomarkers Fractional Exhaled Nitric Oxide (FENO): FENO was measured using a NIOX chemiluminescence analyser (Aerocrine AB, Solna, Sweden) in accordance with the 2005 American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations.[17] The flow rate of 50 mL/s was used for standardization Fractional Exhaled Nitric Oxide (FENO): FENO was measured using a NIOX chemiluminescence analyser (Aerocrine AB, Solna, Sweden) in accordance with the 2005 American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations.[17] The flow rate of 50 mL/s was used for standardization Blood Samples: Blood samples were collected to measure absolute eosinophil count, serum total IgE, vitamin D, high sensitivity C-reactive protein (Hs-CRP), and interleukins 4, 5, 6, 8, 13, 17, and 33. These biomarkers were quantified using enzyme-linked immunosorbent assay (ELISA) with standardized kits according to the manufacturer’s protocol (Diaclone, Calbiotech).® Blood Samples: Blood samples were collected to measure absolute eosinophil count, serum total IgE, vitamin D, high sensitivity C-reactive protein (Hs-CRP), and interleukins 4, 5, 6, 8, 13, 17, and 33. These biomarkers were quantified using enzyme-linked immunosorbent assay (ELISA) with standardized kits according to the manufacturer’s protocol (Diaclone, Calbiotech).® Statistical analysis The collected data were converted into variables, coded, and entered into Microsoft Excel. Data from different stages of the study were compared, and correlations were assessed to identify relationships among the variables. Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS), version 25. Group comparisons were performed using analysis of variance (ANOVA) for continuous variables and the Chi-square test for categorical variables, as appropriate. Associations between parameters were evaluated using Spearman’s correlation coefficient. A P value of less than 0.05 was considered statistically significant. RESULTS Demographic and clinical characteristics A total of 168 patients were enrolled in this study, with 56 patients in each group. The demographic and clinical profiles of the asthma, COPD, and ACO groups are summarized in Table 1. Patients with ACO were younger than those with COPD but older than asthma patients (P < 0.0001). BMI followed an intermediate pattern in the ACO group, falling between the asthma and COPD groups (P = 0.002). As expected, smoking history differed significantly, with the majority of asthma patients being never-smokers (98.2%), while the COPD and ACO groups had higher proportions of current and former smokers. The duration of symptoms was longest in the ACO group, significantly exceeding that of both the asthma and COPD groups (P < 0.0001). Allergic features were most prevalent in the asthma group, with 71% reporting allergic rhinitis and 46.4% showing skin prick test positivity against common aeroallergens, compared to 21.4% and 8.9% in the COPD group, respectively. The ACO group again demonstrated an intermediate phenotype for these parameters (53.6% rhinitis, 35.7% SPT positive). Table 1Demographic, clinical, and spirometric parameters of the study groupsParameterAsthma (n=56)COPD (n=56)ACO (n=56) P Age (years), mean±SD35.9±12.560.7±8.856±9.2<0.000Sex (M/F)35:2146:1040:16<0.000BMI (kg/m²), mean±SD25.2±4.422.5±3.823.7±3.8<0.002Smoking history (former/current/never)0/1/5511/39/69/13/17<0.000Pack years, mean±SD0.09±0.621.6±14.213.5±15.20.130Duration of symptoms (years), mean±SD10.1±76.25±4.513.6±12.1<0.000Allergic rhinitis (%)71%21.4%53.6%<0.000mMRC dyspnoea scale-2.3±0.682±0.71<0.000Exacerbations (%)64.3%60.6%73.2%0.361SGRQ score, mean±SD30.8±11.138.6±1246.8±13.2<0.000Skin prick test positivity test against common aeroallergens (%)46.4%8.9%35.7%<0.001FEV1 (L, post-BD)2.1±0.86#1.24±0.421.31±0.53 **<0.000FEV1 (% predicted, post-BD)72.6±23.6#50.7±18.650.8±18.9 **<0.000FVC (L, post-BD)3.4±0.53.21±0.73.16±0.60.122FVC% (% predicted, post BD)90.6±17.383.9±21.383.6±18.70.130FEV1/FVC ratio65.7±15#48.4±1248.3±12.4 **<0.000Bronchodilator responsiveness: ΔFEV1 (ml)349.1±185#102.1±98362±157.3#<0.000Bronchodilator responsiveness: ΔFEV1 (%)21.7±11.2#8.5±7.525±12.6#<0.000**Compared with asthma group, P<0.05; #Compared with COPD group, P<0.05. COPD=Chronic obstructive pulmonary disease, ACO=Asthma–COPD overlap, SD=Standard deviation, BMI=Body mass index, SGRQ=St George’s Respiratory Questionnaire, BD=Bronchodilator, FVC=Forced vital capacity Demographic, clinical, and spirometric parameters of the study groups **Compared with asthma group, P<0.05; #Compared with COPD group, P<0.05. COPD=Chronic obstructive pulmonary disease, ACO=Asthma–COPD overlap, SD=Standard deviation, BMI=Body mass index, SGRQ=St George’s Respiratory Questionnaire, BD=Bronchodilator, FVC=Forced vital capacity Spirometric parameters Spirometric analysis revealed distinct patterns of lung function impairment [Table 1]. Post-bronchodilator FEV1 and the FEV1/FVC ratio were significantly lower in both the COPD and ACO groups compared to the asthma group (P < 0.0001). While the mean FEV1 and FEV1/FVC were nearly identical between the COPD and ACO groups, their response to bronchodilator differed markedly. The bronchodilator response (both absolute change in FEV1 and percent change) was significantly greater in the asthma and ACO groups compared to the COPD group (P < 0.0001), with no significant difference between asthma and ACO. Inflammatory biomarker profiles The inflammatory biomarker profiles are detailed in Table 2 and revealed a consistent pattern of ACO as an intermediate phenotype. Biomarkers associated with type 2 inflammation were most elevated in the asthma group. Absolute eosinophil count, serum total IgE, and FeNO were significantly higher in asthma compared to COPD (P < 0.0001). For each of these markers, the ACO group displayed intermediate values that were significantly different from both the asthma and COPD groups. Table 2Comparison of inflammatory biomarkers between the study groupsInflammatory biomarkerAsthma group Mean±SDCOPD group Mean±SDACO group Mean±SDPAEC (cells/mcL)440.8±282.5#183.7±132.9353±248.6*#<0.000S. Total IgE (IU/mL)740.6±645#260.7±211593±492*#<0.000FeNO (ppb)28.9±18.2#9.4±5.116.7±14.9*#<0.000Vitamin D (ng/mL)26.1±17.6#36.1±25.832.6±20.30.047HsCRP (mg/L)7.2±3.7#9.3±2.57.9±3.30.002IL-4 (pg/mL)6.8+2.1#5.9±1.87±1.9#<0.006IL-5 (pg/mL)52±30.2#41.2±24.945.5±26.4<0.02IL-6 (pg/mL)5.38±5#7.9±7.76±4.9<0.04IL-8 (pg/mL)25.8±24.8#36.3±29.826.9±25.5<0.02IL-13 (pg/mL)43.4±13.242±14.443.3±17.4<0.859IL-17 (pg/mL)41.2±1441.1±14.741.9±13.3<0.951IL-33 (pg/mL)64.1±55.757.6±35.5759.35±52.5<0.641*Compared with the asthma group, P<0.05; #Compared with the COPD group, P<0.05. COPD=Chronic obstructive pulmonary disease, ACO=Asthma–COPD overlap, AEC=Absolute eosinophil count Comparison of inflammatory biomarkers between the study groups *Compared with the asthma group, P<0.05; #Compared with the COPD group, P<0.05. COPD=Chronic obstructive pulmonary disease, ACO=Asthma–COPD overlap, AEC=Absolute eosinophil count Levels of Hs-CRP were significantly elevated in the COPD group compared to the asthma group (P < 0.002), with the ACO group showing intermediate levels. Conversely, Vitamin D levels were significantly lower in the asthma group compared to the COPD group (P = 0.047), with ACO patients again exhibiting intermediate values. Post hoc analysis confirmed that the differences were significant only between the asthma and COPD groups for both markers. Analysis of cytokine levels further delineated the inflammatory patterns. The Th2 cytokines IL-4 and IL-5 were significantly higher in the asthma group than in the COPD group (P < 0.006 and P < 0.02, respectively). Notably, IL-4 levels in the ACO group were significantly higher than in the COPD group (P < 0.05). In contrast, the levels of IL-6 and IL-8 were significantly elevated in the COPD group compared to asthma (P < 0.04 and P < 0.02, respectively). For IL-5, IL-6, and IL-8, the ACO group demonstrated intermediate values that were not statistically distinct from either pure disease group. No significant differences were observed among the three groups for IL-13, IL-17, or IL-33. Health-related quality of life Assessment with the SGRQ revealed significant differences in health-related quality of life. The total SGRQ score was highest (indicating the worst quality of life) in the ACO group (46.8 ± 13.2), followed by the COPD (38.6 ± 12.0) and asthma (30.8 ± 11.1) groups (P < 0.0001), indicating the greatest functional and symptomatic burden in patients with the overlap syndrome. Correlations between inflammatory biomarkers and clinical parameters Spearman correlation was assessed between inflammatory biomarkers and clinical parameters (age, BMI, duration of symptoms, pack-years, FEV1/FVC, FEV1, BDR, and FVC). In the asthma group, a moderate positive correlation was observed between Hs-CRP and BMI (r = 0.460, P < 0.001, Figure 1). In the COPD group, IL-4 demonstrated a weak negative correlation with the FEV1/FVC ratio (r = -0.291, P = 0.03, Figure 1). Within the ACO group, IL-4 showed a weak positive correlation with BMI (r = 0.285, P = 0.03, Figure 2), while IL-6 was negatively correlated with bronchodilator response (r = -0.293, P = 0.028, Figure 2). A weak positive correlation was also found between IL-17 and the duration of symptoms in ACO patients (r = 0.282, P = 0.035, Figure 2). Correlation between various parameters in Asthma and COPD groups (This figure depicts only the parameters that showed significant correlations (P < 0.05) in the study) Correlation between various parameters in ACO group (This figure depicts only the parameters that showed significant correlations (P < 0.05) in the study) DISCUSSION The present study aimed to analyse demographic and clinical characteristics, lung function, quality of life, and inflammatory biomarkers in patients with asthma, COPD, and ACO, as well as to study the correlation between them, if any. Our findings indicated that ACO patients were younger than those with COPD but older than those with asthma. Additionally, the mean BMI of ACO patients was intermediate between that of asthma and COPD patients, consistent with observations from previous studies.[781819] The proportion of current and former smokers was higher in the COPD group compared to the ACO group, a pattern also reported in a prior study.[8] Although exacerbations were more common in the ACO group compared to the asthma and COPD groups, this difference was not statistically significant. Nevertheless, a similar trend has been documented in an earlier study, indicating a higher incidence of exacerbations among patients with ACO relative to those with COPD.[7] When comparing FEV1 among the study groups, both the COPD and ACO groups exhibited lower FEV1 values compared to the asthma group. Although the difference in FEV1 between the COPD and ACO groups was not statistically significant, COPD patients had a slightly lower FEV1 than ACO patients, consistent with previous studies.[782021] The bronchodilator response showed that the ACO group had a higher bronchodilator response than the COPD group. Although the difference between the asthma and ACO groups was not statistically significant, the ACO group had a slightly higher bronchodilator response than the asthma group. These findings are in line with a previous study.[20] In our study, the asthma group exhibited significantly higher AEC and serum IgE levels compared to the ACO group, with the COPD group showing the lowest levels.[192122] Similarly, FeNO levels were significantly elevated in the asthma group compared to the ACO group, and were lowest in the COPD group, consistent with earlier studies.[1119] We observed significantly higher mean HsCRP levels in COPD patients than in asthma patients, while the ACO group showed intermediate levels that did not significantly differ from either group in post hoc analysis. This overall pattern agrees with Sy Duong-Quy et al.,[19] who reported a significantly higher proportion of elevated CRP in COPD compared to asthma or ACO. Vitamin D levels differed significantly across groups, with the lowest concentrations in asthma versus COPD. ACO demonstrated intermediate values with no significant difference from either group. When comparing interleukin levels across the groups, IL-4 and IL-5 were significantly elevated in asthma patients compared to those with COPD. Conversely, IL-6 and IL-8 levels were significantly higher in the COPD group than in the asthma group. The ACO group exhibited intermediate values for these cytokines. However, the differences were not statistically significant, except for IL-4, which was significantly higher in ACO compared to COPD. Our findings are in agreement with those of Huang A.-X. et al.,[22] who reported higher IL-4 levels in ACO compared to COPD. Similarly, Pérez de Llano et al.[11] observed the highest IL-5 concentrations in asthma, the lowest in COPD, and intermediate levels in ACO, with statistical significance noted only between asthma and COPD—findings consistent with our results. In contrast, Ghosh et al.[21] reported higher IL-5 levels in ACO than in asthma. This discrepancy may be explained by their smaller sample size and the higher cumulative smoking exposure in their asthma cohort (16.8 vs. 0.1 pack-years in our study). Previous studies have also highlighted elevated IL-6 levels in COPD. One study demonstrated significantly higher IL-6 concentrations in the induced sputum of COPD patients compared to those with asthma.[23] In line with this, a systematic review and meta-analysis by Wei et al.[24] reported higher serum IL-6 levels in stable COPD patients compared to healthy controls. However, Pérez de Llano et al.[11] found a different trend, reporting the highest median IL-6 levels in asthma, followed by ACO, and the lowest in COPD. The atypical pattern in that study may be related to the older age of the asthma cohort (mean age: 61.8 years vs. 35.9 years in our study) and a higher prevalence of smoking among participants, possibly contributing to elevated IL-6 levels in both the asthma and ACO groups. The same study also reported higher IL-8 levels in COPD and ACO compared to asthma.[11] While IL-17A is known to promote neutrophilic inflammation and has shown elevated serum levels in severe asthma and stable COPD subgroups in previous studies,[2526] our findings revealed nearly identical IL-17A levels across the asthma, COPD, and ACO groups. This lack of significant difference is consistent with other studies that have compared circulating IL-17A levels among these conditions.[1127] Similarly, IL-13 levels in our cohort did not differ significantly among the groups, which is consistent with prior research.[1121] Data comparing IL-33 levels across these diseases remain limited. IL-33 has been primarily associated with Th2 responses in asthma, while its role in COPD is emerging.[28] Recently, IL-33 has been suggested to play an important role in COPD pathogenesis.[28] Some reports have noted elevated plasma IL-33 levels in COPD patients, correlating with disease severity and eosinophilia.[2829] In our study, mean IL-33 levels were higher in asthma compared to COPD and ACO; however, the difference was not statistically significant. Larger studies are needed to further clarify the role of IL-33 in chronic airway diseases. The presence of Th2 (type 2 T-helper) inflammation was highlighted by the elevated levels of FeNO, AEC, and IgE observed in the asthma group and, to a lesser extent, in the ACO group. Th2 cytokines, particularly IL-4, IL-5, and IL-13, play a crucial role in driving eosinophilic inflammation and IgE production.[9] These biomarkers of Th2 inflammation help differentiate asthma and ACO from COPD, which typically lacks this inflammatory profile. Notably, within the cytokine profile, IL-4 levels in ACO were significantly higher than in COPD and comparable to asthma. While IL-5 levels also trended higher in ACO compared to COPD, these differences did not reach statistical significance. This pattern, particularly the significant elevation in IL-4, reinforces a shared Th2 inflammatory mechanism between asthma and ACO. The elevation in established biomarkers (FeNO, AEC, IgE) and key cytokines like IL-4 supports the hypothesis that ACO exhibits overlapping Th2-driven features with asthma. Health-related quality of life (HRQOL) was compared between the groups using the SGRQ score. The SGRQ score was significantly higher in the ACO group compared to the COPD and asthma groups, indicating that patients with ACO had the poorest HRQOL among the three. These findings are consistent with previous studies.[830] For instance, the COPD gene study investigators compared individuals with ACO to those with COPD alone and reported poorer quality of life in the ACO group.[30] Spearman correlation analysis was performed between the inflammatory biomarkers and various parameters in the asthma, COPD, and ACO groups. In the asthma group, a moderate positive correlation was noted between hs-CRP and BMI (r = 0.460, P < 0.001, Figure 1), consistent with earlier reports linking obesity and systemic inflammation in asthma.[3132] Although the exact relationship between CRP and asthma remains unclear, prior studies have documented elevated CRP levels in obese individuals with asthma.[31] In the COPD group, IL-4 showed a weak negative correlation with FEV1/FVC (r = –0.291, P = 0.03, Figure 1). This aligns partly with the findings of Ankit Mitra et al.,[33] who reported an inverse association between IL-4 and both FEV1 and FEV1/FVC. However, in our study, the correlation between IL-4 and FEV1 was not statistically significant. In ACO group, IL-4 exhibited a weak positive correlation with BMI (r = 0.285, P = 0.03, Figure 2), though supporting data in ACO is lacking. IL-6 correlated negatively with bronchodilator response (r = –0.293, P = 0.028, Figure 2), consistent with IL-6 pathway involvement in fixed airflow limitation.[24] Additionally, IL-17A correlated weakly and positively with disease duration (r = 0.282, P = 0.035, Figure 2) in ACO patients, suggesting a possible role of Th17-mediated inflammation in the chronicity of disease. Although many of our findings are in agreement with previous literature, we believe the strength of this work lies in providing a comprehensive biomarker profile in a single cohort, including FeNO, eosinophils, IgE, vitamin D, hs-CRP, and multiple interleukins. To the best of our knowledge, this is the first study from India to present such an extensive inflammatory biomarker and quality-of-life profile simultaneously across asthma, COPD, and ACO patients. This study, however, has certain limitations. We did not include a healthy control group, which has been used in many previous studies to compare inflammatory biomarkers. Additionally, we could not completely eliminate selection bias. We also did not exclude current smokers from our study, which could influence the measurement of inflammatory biomarkers. However, we did exclude patients with systemic diseases and recent oral corticosteroid use, which could potentially affect the measurement of inflammatory biomarkers. Another limitation is that the study was conducted between 2019 and 2020, and therefore represents data that may not reflect the most recent trends or management practices. A larger, multi-year dataset would provide greater external validity. Furthermore, we used GINA 2018 and GOLD 2018 guidelines for categorization, which were the prevailing standards during the study period but have since been updated. CONCLUSION This study provides critical insights into the differentiation of ACO from asthma and COPD using inflammatory biomarkers and clinical features. The findings indicate that while biomarkers such as FeNO, blood eosinophil count, and IgE are useful in supporting the diagnosis of ACO, they alone may not be sufficient for clear differentiation without considering a combination of other factors. The study reveals that plasma levels of IL-4 and IL-5 are significantly higher in asthma patients compared to COPD patients, whereas IL-6 and IL-8 are more elevated in COPD patients. Interestingly, IL-4 was significantly higher in the ACO group than in the COPD group, which suggests its potential role in distinguishing ACO from COPD. However, the study acknowledges that these markers cannot completely differentiate ACO from asthma and COPD in isolation, highlighting the importance of a multifactorial approach that includes clinical assessment, spirometry, and other relevant biomarkers. Furthermore, the assessment of health-related quality of life using the SGRQ questionnaire demonstrated that ACO patients experienced the worst quality of life among the groups studied. This underscores the need for tailored therapeutic strategies that address the unique challenges faced by ACO patients. Consent to participate Informed written consent was obtained from all participants before their inclusion in the study. All patients signed a consent form after being informed of the nature and purpose of the study. The form is retained securely in the institutional records. Ethical approval The study protocol was reviewed and approved by the Institutional Ethics Committee of Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India. Conflicts of interest There are no conflicts of interest.